Fosun’s IPO Plan For India’s Gland Hits Multiple Targets
Need For Funds, Military Tensions With India In Backdrop
Executive Summary
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
You may also be interested in...
Coronavirus Update: Pfizer Vaccine Candidates Gain Fast-Track Status
The granting of fast-track status is a clear signal that the US FDA wants to maintain its high standards of drug and vaccine appraisal.
KKR Deal To Bolster JB Chemicals’ Expansion Efforts
US private equity firm KKR to acquire a majority stake in JB Chemicals, accelerating the Indian group's growth plans in branded formulations. Post a 54% stake acquisition for $414m via part-purchase from the founders and an open offer at INR745/share, KKR's final stake could rise to 64.9% if founders offer more shares.
India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise
A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.
Need a specific report? 1000+ reports available
Buy Reports